Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefepime
Drug ID BADD_D00386
Description Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
Indications and Usage For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Marketing Status Prescription; Discontinued
ATC Code J01DE01
DrugBank ID DB01413
KEGG ID D02376
MeSH ID D000077723
PubChem ID 5479537
TTD Drug ID D0A1CB
NDC Product Code 60505-6146; 66288-8100; 44567-130; 66794-210; 10402-003; 0409-9735; 0409-9566; 63323-326; 52946-0919; 44567-240; 60505-6145; 66794-209; 0338-1301; 60505-6144; 44567-241; 63323-340; 44567-131; 60505-6147
Synonyms Cefepime | Cefepim | Cefepime Hydrochloride | Maxipime | Axépim | Quadrocef | BMY 28142 | BMY-28142 | BMY28142
Chemical Information
Molecular Formula C19H24N6O5S2
CAS Registry Number 88040-23-7
SMILES C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophil count13.01.06.021--Not Available
Eosinophilia01.02.04.001--
Epilepsy17.12.03.0020.000213%Not Available
Erythema23.03.06.0010.000532%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000213%
Extravasation08.01.03.008--Not Available
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.0040.000213%
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.0020.000213%Not Available
Haematocrit13.01.05.017--Not Available
Haemoglobin13.01.05.018--Not Available
Haemolysis01.06.04.002--
Haemolytic anaemia01.06.03.002--Not Available
Hallucination19.10.02.0020.000319%
Headache17.14.01.001--
Heart rate increased13.14.04.0020.000213%Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatocellular injury09.01.07.0080.000213%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.000319%
Hypersensitivity10.01.03.0030.000426%
Hypocalcaemia14.04.01.004--
Hypoglycaemia14.06.03.001; 05.06.03.0010.000213%
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000319%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages